Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Altimmune to Participate at the Noble Capital 14th Annual Investor Conference


Posted on: 22 Jan 18

GAITHERSBURG, Md., Jan. 22, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq:ALT), a clinical-stage immunotherapeutics company, announced today that Bill Enright, President and Chief Executive Officer, will provide a corporate overview at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference, being held January 29-30, 2018 at the W Hotel, Fort Lauderdale, Florida.

14th Annual Investor Conference Presentation Details
Date:   Tuesday, January 30, 2018
Time:   2:30pm Eastern Time
Location:   W Hotel, Ft. Lauderdale, Florida, Studio 2
Webcast:   http://noble.mediasite.com/mediasite/Play/6a0d0193d3f1470e9bf8607c7f1ba1161d

A high-definition, video webcast of the presentation will be available the following day on the Company's web site www.altimmune.com and as part of a complete catalog of presentations available at Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. You will require a Microsoft SilverLight viewer (a free download from the presentation link) to participate. The webcast and presentation will be archived on the company's website and on the Noble websites for 90 days following the event.

About Altimmune
Altimmune is a clinical-stage immunotherapeutics company focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease including NasoVAX, a Phase 2 seasonal influenza vaccine candidate, and HepTcell, a Phase 1 immunotherapeutic candidate for the potential cure of chronic hepatitis B. The company also has two United States government funded, next-generation anthrax vaccine candidates that are intended to improve protection and safety while having favorable dosage and storage requirements compared to other anthrax vaccines.

Contacts:
Bill Enright 
President and CEO
Phone: 240-654-1450
Email: enright@altimmune.com

Ashley Robinson
Managing Director LifeSci Advisor
Phone: 617-535-7742
Email: arr@lifesciadvisors.com

GlobeNewswire
globenewswire.com

Last updated on: 22/01/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.